Impella Improves Survival from Cardiogenic Shock, but at a Price
Cardiogenic shock is a condition in which the heart is unable to pump with enough force to sustain life. Impella CP is a small pump implanted in the heart’s left ventricle to increase blood flow. In an international, multicenter study of patients in cardiogenic shock following a heart attack, published May 2024 in the New England Journal of Medicine, Impella saved more lives than standard treatment, but with a much higher rate of complications.
The post Heart Beat – July 2024 appeared first on Heart Advisor.